Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review
The predominant cause of cancer mortality is metastasis. The major impediment to cancer cure is the intrinsic or acquired resistance to currently available therapies. Cancer is heterogeneous at the genetic, epigenetic, and metabolic levels. And, while a molecular-targeted drug may be pathway-precise, it can still fail to achieve wholesome cancer-precise toxicity. In the current review, we discuss the strategic differences between targeting the strengths of cancer cells in phenotypic plasticity and heterogeneity and targeting shared vulnerabilities of cancer cells such as the compromised integrity of membranous organelles. To better recapitulate subpopulations of cancer cells in different phenotypic and functional states, we developed a schematic combination of 2-dimensional culture (2D), 3-dimmensional culture in collagen I (3D), and mammosphere culture for stem cells (mammosphere), designated as Scheme 2D/3D/mammosphere. We investigated how the tumor suppressor maspin may limit carcinoma cell plasticity and affect their context-dependent response to drugs of different mechanisms including docetaxel, histone deacetylase (HDAC) inhibitor MS-275, and ionophore antibiotic salinomycin. We showed that tumor cell phenotypic plasticity is not an exclusive attribute to cancer stem cells. Nonetheless, three subpopulations of prostate cancer cells, enriched through Scheme 2D/3D/mammosphere, show qualitatively different drug responses. Interestingly, salinomycin was the only drug that effectively killed all three cancer cell subpopulations, irrespective of their capacity of stemness. Further, Scheme 2D/3D/mammosphere may be a useful model to accelerate the screening for curative cancer drugs while avoiding costly characterization of compounds that may have only selective toxicity to some, but not all, cancer cell subpopulations.
KeywordsDrug resistance Heterogeneity Cancer stem cells Proliferation Transient quiescence Epithelial-to-mesenchymal transition (EMT) Integrity of membranous subcellular structures Drug screening strategy Cell death Cell survival Cancer strength Cancer vulnerability Maspin Scheme 2D/3D/mammosphere Docetaxel MS-275 Salinomycin
This work was supported by the NIH Grant P30CA022453 (to the Karmanos Cancer Institute (KCI) with Sheng, S. as a program leader), the Ruth Sager Memorial Fund (to Sheng, S.), the KCI Pilot Project Grant 25S5Z (to Sheng, S.), the KCI Prostate Cancer Research Pilot Project Grant (to Sheng, S.), and the KCI Tumor Biology and Microenvironment Program Pilot Project (to Sheng, S).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest
- 2.Global Burden of Disease Cancer, Fitzmaurice, C., Akinyemiju, T. F., Al Lami, F. H., Alam, T., Alizadeh-Navaei, R., et al. (2018). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2018.2706.
- 9.Erickson, B. K., Rose, C. M., Braun, C. R., Erickson, A. R., Knott, J., McAlister, G. C., et al. (2017). A strategy to combine sample multiplexing with targeted proteomics assays for high-throughput protein signature characterization. Molecular Cell, 65(2), 361–370. https://doi.org/10.1016/j.molcel.2016.12.005.Google Scholar
- 12.Wolf, C. R., & Henderson, C. J. (1998). Use of transgenic animals in understanding molecular mechanisms of toxicity. The Journal of Pharmacy and Pharmacology, 50(6), 567–574.Google Scholar
- 13.Ho, B. X., Pek, N. M. Q., & Soh, B. S. (2018). Disease modeling using 3D organoids derived from human induced pluripotent stem cells. International Journal of Molecular Sciences, 19(4). https://doi.org/10.3390/ijms19040936.
- 14.Ozcelikkale, A., Moon, H. R., Linnes, M., & Han, B. (2017). In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology, 9(5). https://doi.org/10.1002/wnan.1460.
- 23.Patel, A., & Fong, L. (2018). Immunotherapy for prostate cancer: where do we go from here?-PART 1: prostate cancer vaccines. Oncology (Williston Park), 32(3), 112–120.Google Scholar
- 27.Thakur, M. K., Heilbrun, L. K., Sheng, S., Stein, M., Liu, G., Antonarakis, E. S., et al. (2016). A phase II trial of ganetespib, a heat shock protein 90 Hsp90 inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Investigational New Drugs, 34(1), 112–118. https://doi.org/10.1007/s10637-015-0307-6.Google Scholar
- 28.Heath, E. I., Hillman, D. W., Vaishampayan, U., Sheng, S., Sarkar, F., Harper, F., et al. (2008). A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clinical Cancer Research, 14(23), 7940–7946. https://doi.org/10.1158/1078-0432.CCR-08-0221.Google Scholar
- 33.Bissell, M. J., Weaver, V. M., Lelievre, S. A., Wang, F., Petersen, O. W., & Schmeichel, K. L. (1999). Tissue structure, nuclear organization, and gene expression in normal and malignant breast. Cancer Research, 59(7 Suppl), 1757–1763s discussion 1763s–1764s.Google Scholar
- 35.Fabregat, I., Fernando, J., Mainez, J., & Sancho, P. (2014). TGF-beta signaling in cancer treatment. Current Pharmaceutical Design, 20(17), 2934–2947.Google Scholar
- 36.Moustakas, A., Pardali, K., Gaal, A., & Heldin, C. H. (2002). Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immunology Letters, 82(1–2), 85–91.Google Scholar
- 38.Melzer, C., von der Ohe, J., & Hass, R. (2018). Concise review: crosstalk of mesenchymal stroma/stem-like cells with cancer cells provides therapeutic potential. Stem Cells. https://doi.org/10.1002/stem.2829.
- 40.D’Angelo, R. C., & Wicha, M. S. (2010). Stem cells in normal development and cancer. Progress in Molecular Biology and Translational Science, 95, 113–158. https://doi.org/10.1016/B978-0-12-385,071-3.00006-X.Google Scholar
- 42.Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., et al. (2018). Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death and Differentiation, 25(3), 486–541. https://doi.org/10.1038/s41418-017-0012-4.Google Scholar
- 43.Tsoi, J., Robert, L., Paraiso, K., Galvan, C., Sheu, K. M., Lay, J., et al. (2018). Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell, 33(5), 890–904 e895. https://doi.org/10.1016/j.ccell.2018.03.017.Google Scholar
- 49.Bernardo, M. M., Kaplun, A., Dzinic, S. H., Li, X., Irish, J., Mujagic, A., et al. (2015). Maspin expression in prostate tumor cells averts stemness and stratifies drug sensitivity. Cancer Research. https://doi.org/10.1158/0008-5472.CAN-15-0234.
- 50.Ohkubo, S., Dalla Via, L., Grancara, S., Kanamori, Y., Garcia-Argaez, A. N., Canettieri, G., et al. (2018). The antioxidant, aged garlic extract, exerts cytotoxic effects on wild-type and multidrug-resistant human cancer cells by altering mitochondrial permeability. International Journal of Oncology, 53(3), 1257–1268. https://doi.org/10.3892/ijo.2018.4452.Google Scholar
- 54.Jia, D., Jolly, M. K., Kulkarni, P., & Levine, H. (2017). Phenotypic plasticity and cell fate decisions in cancer: insights from dynamical systems theory. Cancers (Basel), 9(7). https://doi.org/10.3390/cancers9070070.
- 56.Zou, Z., Anisowicz, A., Hendrix, M. J., Thor, A., Neveu, M., Sheng, S., et al. (1994). Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science, 263(5146), 526–529.Google Scholar
- 60.Kaplun, A., Dzinic, S., Bernardo, M., & Sheng, S. (2012). Tumor suppressor maspin as a rheostat in HDAC regulation to achieve the fine-tuning of epithelial homeostasis. Critical Reviews in Eukaryotic Gene Expression, 22(3), 249–258.Google Scholar
- 63.Biliran Jr., H., & Sheng, S. (2001). Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin. Cancer Research, 61(24), 8676–8682.Google Scholar
- 65.Cher, M. L., Biliran, H. R., Bhagat, S., Meng, Y. H., Che, M. X., Lockett, J., et al. (2003). Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proceedings of the National Academy of Sciences of the United States of America, 100(13), 7847–7852. https://doi.org/10.1073/pnas.1331360100.Google Scholar
- 66.Domingo-Domenech, J., Vidal, S. J., Rodriguez-Bravo, V., Castillo-Martin, M., Quinn, S. A., Rodriguez-Barrueco, R., et al. (2012). Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell, 22(3), 373–388. https://doi.org/10.1016/j.ccr.2012.07.016.Google Scholar